Vanguard Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-2,972,383
| Closed | -$33.3M | – | 4136 |
|
|
2017
Q3 | $33.3M | Buy |
2,972,383
+15,012
| +0.5% | +$166K | ﹤0.01% | 2254 |
|
|
2017
Q2 | $32.5M | Buy |
2,957,371
+8,525
| +0.3% | +$85.3K | ﹤0.01% | 2236 |
|
|
2017
Q1 | $28.9M | Buy |
2,948,846
+248,785
| +9% | +$2.48M | ﹤0.01% | 2274 |
|
|
2016
Q4 | $29.2M | Buy |
2,700,061
+96,541
| +4% | +$965K | ﹤0.01% | 2234 |
|
|
2016
Q3 | $26.7M | Buy |
2,603,520
+162,448
| +7% | +$1.77M | ﹤0.01% | 2235 |
|
|
2016
Q2 | $31.9M | Buy |
2,441,072
+476,472
| +24% | +$6.24M | ﹤0.01% | 2113 |
|
|
2016
Q1 | $21.6M | Buy |
1,964,600
+172,564
| +10% | +$1.53M | ﹤0.01% | 2266 |
|
|
2015
Q4 | $16.5M | Buy |
1,792,036
+90,650
| +5% | +$759K | ﹤0.01% | 2390 |
|
|
2015
Q3 | $11.8M | Sell |
1,701,386
-292,410
| -15% | -$2.5M | ﹤0.01% | 2518 |
|
|
2015
Q2 | $19.6M | Buy |
1,993,796
+24,609
| +1% | +$224K | ﹤0.01% | 2366 |
|
|
2015
Q1 | $17.4M | Buy |
1,969,187
+154,824
| +9% | +$1.23M | ﹤0.01% | 2380 |
|
|
2014
Q4 | $15.9M | Buy |
1,814,363
+350,111
| +24% | +$2.83M | ﹤0.01% | 2344 |
|
|
2014
Q3 | $10.1M | Buy |
1,464,252
+6,284
| +0.4% | +$37.7K | ﹤0.01% | 2490 |
|
|
2014
Q2 | $7.67M | Buy |
1,457,968
+119
| +0% | +$579 | ﹤0.01% | 2641 |
|
|
2014
Q1 | $6.63M | Buy |
1,457,849
+69,195
| +5% | +$334K | ﹤0.01% | 2687 |
|
|
2013
Q4 | $7M | Buy |
1,388,654
+19,278
| +1% | +$92.8K | ﹤0.01% | 2622 |
|
|
2013
Q3 | $6.94M | Buy |
1,369,376
+29,857
| +2% | +$166K | ﹤0.01% | 2568 |
|
|
2013
Q2 | $6.64M | Buy |
+1,339,519
| New | +$6.37M | ﹤0.01% | 2516 |
|
Vanguard Group's SCLN Position: Q4 2017 in Review
Vanguard Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 2,972,383 shares — an estimated $33.3M sold.
Vanguard Group first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $33.3M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Vanguard Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Vanguard Group sold 2,972,383 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $33.3M.
- Vanguard Group first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Vanguard Group's Sciclone Pharmaceuticals Inc position peaked at $33.3M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Vanguard Group's 13F filing for Q4 2017, filed 14 Feb 2018.